DROPLET MICROFLUIDIC BASED CD3 DIMERIZATION FOR T-CELL PRECISION ACTIVATION

Huang Lai, Wen Yin, Yi Liu, Xiaozhe Zhang, Guojie Luo, Xiaodong Lin, Mo Yang2024 · DOI

Abstract

T-cell activation is essential in immunotherapy, and the CD3 dimerization on T-cell is a preliminary prerequisite for activation. However, achieving precise and efficient CD3 dimerization using conventional bulk technologies remains challenging. In this study, we present a novel approach by integrating a liquid metal-enabled pico-injector into a droplet microfluidic platform to precisely deliver a designed dimeric DNA assembly for CD3 dimerization on T-cells. We evaluate the efficiency of the CD3 dimerization and demonstrate a remarkable full-rate dimerization that is significant for the subsequent activation.

Introduction

T-cell activation serves as the cornerstone of modern immunotherapy. A critical, yet often difficult to control, prerequisite for this activation is CD3 dimerization, where specific receptors on the T-cell surface are brought into close proximity. Traditional "bulk" methods, such as mixing reagents in a test tube, lack the precision required to control this process at the single-cell level. Given the high variability in immunotherapy responses among patients, there is a pressing need for technologies that can precisely deliver activating agents to individual cells and quantify the resulting dimerization efficiency without the noise inherent in bulk processing.

Methods

The researchers developed an integrated microfluidic device designed for high-precision single-cell manipulation. The workflow consists of two primary stages: single-cell droplet encapsulation and liquid metal-enabled pico-injection.

Integrated microfluidic platform showing the device schematic (a), droplet generation (b), and the pico-injection process (c).

Single-Cell Droplet Encapsulation

Jurkat cells, serving as a model for T-cells, were encapsulated into picoliter-sized aqueous droplets using a microfluidic generator. To maximize the number of droplets containing exactly one cell, the team optimized cell density based on Poisson statistics, testing densities from $3 \times 10^5$ to $1 \times 10^6$ cells/ml.

Liquid Metal Pico-Injection

The device's core innovation is the integration of liquid metal electrodes. As a cell-carrying droplet passes these electrodes, an external electrical signal triggers the injection of a precise volume (ranging from 0.07 nL to 20 nL) of a dimeric DNA aptamer assembly. This assembly consists of two aptamers (B1 and B2) designed to bind CD3 receptors, linked by a fluorescently tagged (FITC) DNA bridge. The use of liquid metal ensures reliable electrical contact and simplifies the fabrication of the micro-electrodes.

Results and Discussion

The platform demonstrated exceptional control over both the physical and biological aspects of the dimerization process.

Characterization and results: (a) cell encapsulation distribution, (b) injection volume calibration, (c) DNA assembly mechanism, and (d) fluorescence imaging of successful dimerization.

Optimization of Cell Loading

Statistical analysis revealed that a cell-to-droplet ratio ($\lambda$) of 0.5 represents the optimal balance for single-cell studies. At this ratio, the system maximizes the yield of single-cell droplets while keeping the occurrence of "doublets" (two cells per droplet) at a manageable level (Figure 2a).

Injection Precision and Dimerization Efficiency

The pico-injector proved highly tunable, with injection volumes showing a linear relationship with applied pressure ($R^2 = 0.9782$, Figure 2b). This allows for fine-tuning the concentration of the DNA activator within each droplet. Most significantly, the platform achieved 100% dimerization efficiency. Using the FITC-labeled DNA linker, the researchers confirmed that every encapsulated cell successfully underwent CD3 dimerization, as evidenced by the clear fluorescent signal on the cell surfaces (Figure 2d).

Conclusion and Future Outlook

This study successfully demonstrates a droplet microfluidic platform capable of inducing full-rate CD3 dimerization on single T-cells. While the current work utilizes Jurkat cell lines, future research will focus on primary T-cells to better replicate clinical conditions. Additionally, while the platform provides a robust framework for assessing early-stage activation, further studies are needed to monitor downstream effects like cytokine production. Scaling this technology through parallelization could eventually provide the throughput necessary for personalized clinical immunotherapies.

Summary updated

Abstract

T-cell activation is essential in immunotherapy, and the CD3 dimerization on T-cell is a preliminary prerequisite for activation.However, achieving precise and efficient CD3 dimerization using conventional bulk technologies remains challenging.In this study, we present a novel approach by integrating a liquid metal-enabled pico-injector into droplet microfluidic platform to precisely deliver a designed dimeric DNA assembly for CD3 dimerization on T-cells.We evaluate the efficiency of the CD3 dimerization and demonstrate a remarkable full-rate dimerization that is significant for the subsequent activation.
BibTeX
@misc{lai2024droplet,
  author = {Huang Lai and Wen Yin and Yi Liu and Xiaozhe Zhang and Guojie Luo and Xiaodong Lin and Mo Yang},
  title = {{DROPLET MICROFLUIDIC BASED CD3 DIMERIZATION FOR T-CELL PRECISION ACTIVATION}},
  year = {2024},
  doi = {10.70477/bnpp4677},
}
Figure